| |||||||||||||||
 Trade In this Item for up to £19.25
Trade in Biotechnology Valuation: An Introductory Guide (The Wiley Finance Series) for an Amazon.co.uk gift card of up to £19.25, which you can then spend on millions of items across the site. Plus, get an extra £5 when you trade in books worth £10 or more until June 30, 2012. Trade-in values may vary (terms apply). Find more products eligible for trade-in.
|
Frequently Bought Together
Product details
|
More About the Author
Product Description
Product Description
∗ The book begins with a short history of the biotechnology industry; this is important as although it is about 30 years old, the first company went public only in 1996, so it is possible to plot the course of investment waves and dips
∗ It examines the European industry and its evolvement, and draws parallels between the similarities and differences between that and the US
∗ Looks at the various companies which make up the biotech industry (therapeutic; life sciences; and the medical technology company) and gives tools for the investor to properly evaluate them
From the Inside Flap
“Keegan states that the valuation of Biotech companies is as much an art as a science. This brief but comprehensive review of the skills and knowledge required, not of just the financial market and sentiment, but also of the technical attributes of a company and the drug development and regulatory hurdles that must be overcome, highlights the importance of the breadth of understanding required. Biotech investing is not for the timid, but it can bring substantial returns. Keegan′s book, punctuated with his personal experience and opinions, is a good place to start.”
—Chris Blackwell, Chief Executive, Vectura Group plc
“A user–friendly, yet thorough discussion of a notoriously difficult topic. Dr Keegan′s book is a fine resource for both business types and academicians.”
—Steve Winokur, Managing Director, CanaccordAdams
“A highly readable and comprehensive explanation of the technical and commercial parameters that influence biotechnology companies at all stages of development, providing clear context for selection from the toolkit of valuation methodologies the author recommends to assess company and product performance, or ascribe value.”
—Dr L.M. Allan, Director, Bioscience Enterprise Programme, University of Cambridge
“A fabulous approach to a difficult topic.”
—Deirdre Y. Gillespie, MD, President & CEO, La Jolla Pharmaceutical Company
Tags Customers Associate with This Product(What's this?)Click on a tag to find related items, discussions, and people.
|
Sell a Digital Version of This Book in the Kindle Store
What Other Items Do Customers Buy After Viewing This Item?
Customer Reviews
The book covers all relevant and unique aspects of valuation in the biotechnology sector. The content is written in a concise and easy to follow language. Definitely recommend!! whether you need to expand your biotech valuation knowledge or as just as a reference book.
Listmania!
Look for similar items by category
Look for similar items by subject
Feedback
- Would you like to update product info or give feedback on images?
- I am the Author, and I want to comment on my book.
- I am the Publisher, and I want to comment on this book.
|
